| Literature DB >> 20300385 |
Nina Rocha Dutra1, Marília Barbosa de Paula, Michelle Dias de Oliveira, Leandro Licursi de Oliveira, Sérgio Oliveira De Paula.
Abstract
The diagnosis of infection by the dengue virus relies, in most cases, on the clinical judgment of the patient, since only a few major centers have clinical laboratories that offer diagnostic tests to confirm the clinical impressions of an infection. At present, routine laboratory diagnosis is done by different kinds of testing. Among them are the methods of serological research, virus isolation, detection of viral antigens, and detection of viral genomes. The continued development of diagnostic tests, which are cheap, sensitive, specific, easy to perform, and capable of giving early diagnosis of the dengue virus infection is still a need. There are also other obstacles that are not specifically related to the technological development of diagnostic methods. For instance, infrastructure of the laboratories, the training of personnel, and the capacity of research of these laboratories are still limited in many parts of Brazil and the world, where dengue is endemic. Clinical laboratories, especially the ones that serve regions with a high incidence of dengue, should be aware of all the diagnostic methods available for routine these days, and choose the one that best suit their working conditions and populations served, in order to save lives.Entities:
Keywords: Clinical laboratory; Dengue; Diagnosis
Year: 2009 PMID: 20300385 PMCID: PMC2840934 DOI: 10.4103/0974-777X.52980
Source DB: PubMed Journal: J Glob Infect Dis ISSN: 0974-777X
Number of reported cases of dengue and dengue hemorrhagic fever in the America by subregion, until October, 2008
| Dengue | DHF | Deaths | |
|---|---|---|---|
| North America | 0 | 0 | 0 |
| Central America | 65289 | 3273 | 4 |
| Andean | 56332 | 3830 | 8 |
| Southern Cone | 736381 | 9957 | 212 |
| Hispanic Caribbean | 3895 | 50 | 11 |
| Caribbean | 3800 | 21 | 3 |
Source: WHO, 2008
Kits available in the market for the detection of anti-dengue antibodies[9]
| Commercial kits | Detected Ig isotypes | Format | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|
| PanBio dengue Duo | IgM/IgG | ELISA | 94[ | 100 approximately[ |
| Dengue duo Rapid dtrip test, PanBio | IgM/IgG | Immunochromatographic test | 76–100 for IgM detection [ | 88–99[ |
| MRL diagnostic dengue | IgM | ELISA | 97,8[ | 100% approximately[ |
| Blot IgMTM, diagnostic biotechnology ltd. | IgM | Immunoblot | 96,9[ | 87,7[ |
| Venture technologies dengue IgM and IgG dot blot | IgM/IgG | Immunoblot | 100[ | 97[ |
| Integrated diagnostics | IgM | Immunochromatographic test | 92,6[ | 94,3[ |
| UMELISA Dengue IgM | IgM | Ultramicro-ELISA | 99,4[ | 94,8[ |
| PanBio dengue IgG dapture ELISA | IgG anti-NS1 | ELISA | 95[ | 94[ |
| PLATELIA™ Dengue NS1 ag, BIO-RAD | IgM anti-NS1 | MAC-ELISA | 93,4[ | 100[ |
Modified from Guzmán and Kouri[9]
Rank in genotypic subtypes
| Serotype DENV | Subtype |
|---|---|
| DENV-1 | I French Polynesia/Fiji/Singapore/Indonésia/Nauru/New Caledonia/Tonga; II Jamaica/French Guyana/New Caledonia/Brazil/México/Aruba/Cuba/Peru/Nicarágua/Thailand/Senegal/Malaysia/Puerto Rico; III Philippines/Thailand |
| DENV-2 | I Puerto Rico/Tahiti/Tonga/Colombia/Mexico/Venezuela/Trinidad; II Taiwan/Philippines/New Guinea/Thailand; III Vietnam/Thailand/Jamaica; IV Indonesia/Seichelles/Burkina Fasos/Sri Lanka; V Ivory Coast/Burkina Faso/Senegal |
| DENV-3 | I Philippines/Malaysia/Indonesia/Tahiti/Fiji; II Thailand; III Sri Lanka/Samoa/India/Mozambique; IV Puerto Rico/Tahiti |
| DENV-4 | I Thailand/Philippines/Sri Lanka; II Tahiti/Puerto Rico/Brazil/New Caledonia/El Salvador/México/Dominica/Indonesia |
Modified from Guzmán and Kouri[9]